PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

With anti-PD-1 antibodies serving as a representative drug, immune checkpoint inhibitors
(ICIs) have become the main drugs used to treat many advanced malignant tumors …

Immune checkpoint inhibitors (ICIs), used to treat many advanced cancers, activate the
immune system to elicit an antitumor response. ICIs can also cause immune-related adverse …

Purpose: Genetic differences in immunity may contribute to toxicity and outcomes with
immune checkpoint inhibitor (CPI) therapy, but these relationships are poorly understood …

Immune checkpoint inhibitor (ICI) treatment has become an important therapeutic option for
various cancer types. Although the treatment is effective, ICI can overstimulate the patient's …

Over the past decade, the use of immune checkpoint inhibitors (ICI) has expanded across a
wide spectrum of oncology indications. Immune-related adverse events (irAE) from ICIs …

Simple Summary Immune checkpoint inhibitors, including monoclonal antibodies directed
against the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) …

Purpose: Immune checkpoint inhibitor (ICI) use can lead to immune-related adverse events
(irAEs) that require treatment with immunosuppressive medications in moderate to severe …

The advent of immune-checkpoint inhibitors (ICIs) has revolutionized the treatment of
malignant solid tumors in the last decade, producing lasting benefits in a subset of patients …

Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of
cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in …